Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies

Swargiary, A., Research Square, doi:10.21203/rs.3.rs-73308/v1
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19ivm.org
In Silico study showing high binding affinity of ivermectin with SARS-CoV-2 RNA-dependent RNA polymerase, suggesting ivermectin as an inhibitor of RdRp.
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N7 Götz, Dengue Jitobaom, Tay, Wagstaff, HIV-1 Wagstaff, Simian virus 40 Wagstaff (B), Zika Barrows, Jitobaom, Yang, West Nile Yang, Yellow Fever Mastrangelo, Varghese, Japanese encephalitis Mastrangelo, Chikungunya Varghese, Semliki Forest virus Varghese, Human papillomavirus Li, Epstein-Barr Li, BK Polyomavirus Bennett, and Sindbis virus Varghese.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins Götz, Kosyna, Wagstaff, Wagstaff (B), inhibits SARS-CoV-2 3CLpro Mody, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing Fauquet, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination Boschi, Scheim, exhibits dose-dependent inhibition of lung injury Abd-Elmawla, Ma, may inhibit SARS-CoV-2 via IMPase inhibition Jitobaom, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation Vottero, may inhibit SARS-CoV-2 RdRp activity Parvez (B), may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation Liu (C), shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-19 DiNicolantonio, Zhang, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage Zhao, may minimize SARS-CoV-2 induced cardiac damage Liu, Liu (B), increases Bifidobacteria which play a key role in the immune system Hazan, has immunomodulatory Munson and anti-inflammatory DiNicolantonio (B), Yan properties, and has an extensive and very positive safety profile Descotes.
Swargiary et al., 9 Sep 2020, preprint, 1 author.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies
Ananta Swargiary
doi:10.21203/rs.3.rs-73308/v1
Purpose: COVID-19, caused by SARS-CoV2 virus is a contagious disease affecting millions of lives throughout the globe. Currently, there are no clinically approved drugs for SARS-CoV2 although some drugs are undergoing clinical trials. The present study investigates the binding property of ivermectin on four important drug targets, spike protein, RNA-dependent RNA polymerase, 3-chymotrypsin-and papainlike proteases of SARS-CoV2. Methods: The 3D structure of ivermectin along with known antiviral drug lopinavir, simeprevir and four nucleotides ATP, GTP, CTP, and UTP were
Ethics approval: NA Consent to participate: NA Consent for publication: Author gives the consent to publish the manuscript
References
Ahmad, Ikram, Ahmad, Rehman, Mushtaq, SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) -A drug repurposing study, Heliyon, doi:10.1016/j.heliyon.2020.e04502
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld et al., Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase, J Biomol Struct Dyn. Doi, doi:10.1126/science.1085658
Benvenuto, Giovanetti, Ciccozzi, Spoto, Angeletti et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1002/jmv.25688
Canga, Prieto, Liebana, Martinez, Vega et al., The Pharmacokinetics and Interactions of Ivermectin in Humans -A Mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
Chen, Yiu, Wong, Prediction of the SARSCoV-2 (2019-nCoV) 3C-like protease (3CL (pro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates, F1000Research, doi:10.12688/f1000research.22457.1
Cui, Li, Shi, Origin and evolution of pathogenic coronaviruses, Nat Rev Microbiol, doi:10.1038/s41579-018-0118-9
Du, He, Zhou, Liu, Zheng et al., The spike protein of SARS-CoV-a target for vaccine and therapeutic development, Nat Rev Microbiol, doi:.org/10.1038/nrmicro2090.ElkyAA
Forni, Cagliani, Clerici, Sironi, Molecular evolution of human coronavirus genomes, Trends Microbiol, doi:10.1016/j.tim.2016.09.001
Gandhi, Lynch, Rio, Mild or Moderate Covid-19, New Engl J Med, doi:10.1056/NEJMcp2009249
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res, doi:.org/10.1016/j.antiviral.2018.09.010
Mckee, Sternberg, Stange, Laufer, Naujokat, Candidate drugs against SARS-CoV-2 and COVID-19, Pharmacol Res, doi:.org/10.1016/j.phrs.2020.104859
Patrì, Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.04.017
Sharun, Dhama, Patel, Pathak, Tiwari et al., Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19, Ann Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w
Touret, Gilles, Barral, Nougairede, Helden et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep, doi:10.1038/s41598-020-70143-6
Trott, Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, e cient optimization and multithreading, J Comput Chem, doi:10.1002/jcc.21334
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Xu, Liu, Weiss, Sg, Ding, Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design, Nucleic Acids Res, doi:10.1093/nar/gkg916
Yin, Mao, Luan, Shen, Shen et al., Structural basis for inhibition of the RNAdependent RNA polymerase from SARS-CoV-2 by remdesivir, Science, doi:10.1126/science.abc1560
Zhou, Fang, Yang, Xu, Lv et al., Identi cation of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach, The FASEB Journal, doi:10.1096/fj.201901624RR
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit